Magnetic Bead Fluorescent Immunoassay Detects Novel Inflammation Marker
By LabMedica International staff writers Posted on 12 Jan 2016 |
A magnetic bead fluorescent sandwich immunoassay has been developed that allows rapid serum measurement of the novel inflammation marker at the point of care (POC) that could aid pneumonia diagnosis.
Pneumonia is an acute infection caused by various bacteria and virus species and the disease is characterized by augmented bronchoalveolar liquid and pus congesting the respiratory tract, resulting in shortness of breath.
Scientists at the Technische Universität München (Munich, Germany) obtained healthy blood donor sera, and patient sera were collected from those with radiologically confirmed pneumonia. A rapid and simple magnetic bead-based immunoassay was developed for the detection of the novel biomarker chitinase-3-like protein 1 (CHI3L1), and also known as YKL40, in an innovative POC-ready device for assistance in the diagnosis of pneumonia.
The study was performed using the ESE Quant Tube Scanner device (QIAGEN Lake Constance GmbH; Stockach Germany). Excitation and emission wavelengths were adjusted to 625 and 680 nm, respectively, to fit the spectral properties of the fluorescent 7-hydroxy-9H-(1,3-dichloro-9,9-dimethylacridin-2-one (DDAO). The ESE Quant Tube Scanner uses a confocal microfluorescence reader, which is small enough to be automatically positioned under each tube. The measurement is repeated every 20 seconds, leading to the recording of the time course of substrate turnover.
The assay procedure, from sample addition to data retrieval, consists of three steps and is performed in less than 20 minutes. The assay has a linear range from 3 ng/mL to 111 ng/mL, with a limit of detection of 2.9 ng/mL. The average recoveries were found between 101 and 111%. The mean calculated serum concentration of patients with pneumonia was 334 ng/mL ± 225 ng/mL (median 300 ng/mL, range 107–821 ng/mL), while serum samples from healthy donors averaged at 50 ng/mL ± 49 ng/mL (median 35 ng/mL, range 9–199 ng/mL).
The authors concluded that the magnetic bead fluorescence immunoassay is a proof of concept that can accurately and rapidly receive protein biomarker data using antibodies bound to magnetic beads in a POC-ready device, providing a simple alternative immunoassay that could help optimize pneumonia diagnosis in low resource settings. The key features of the presented assay are a rapid fluorescence measurement below 20 minutes, a detection limit that corresponds well to the lower reference range of this inflammation serum marker, and usage of an inexpensive and robust device. The study was published in the December 2015 issue of the Journal of Immunological Methods.
Related Links:
Technische Universität München
QIAGEN Lake Constance GmbH
Pneumonia is an acute infection caused by various bacteria and virus species and the disease is characterized by augmented bronchoalveolar liquid and pus congesting the respiratory tract, resulting in shortness of breath.
Scientists at the Technische Universität München (Munich, Germany) obtained healthy blood donor sera, and patient sera were collected from those with radiologically confirmed pneumonia. A rapid and simple magnetic bead-based immunoassay was developed for the detection of the novel biomarker chitinase-3-like protein 1 (CHI3L1), and also known as YKL40, in an innovative POC-ready device for assistance in the diagnosis of pneumonia.
The study was performed using the ESE Quant Tube Scanner device (QIAGEN Lake Constance GmbH; Stockach Germany). Excitation and emission wavelengths were adjusted to 625 and 680 nm, respectively, to fit the spectral properties of the fluorescent 7-hydroxy-9H-(1,3-dichloro-9,9-dimethylacridin-2-one (DDAO). The ESE Quant Tube Scanner uses a confocal microfluorescence reader, which is small enough to be automatically positioned under each tube. The measurement is repeated every 20 seconds, leading to the recording of the time course of substrate turnover.
The assay procedure, from sample addition to data retrieval, consists of three steps and is performed in less than 20 minutes. The assay has a linear range from 3 ng/mL to 111 ng/mL, with a limit of detection of 2.9 ng/mL. The average recoveries were found between 101 and 111%. The mean calculated serum concentration of patients with pneumonia was 334 ng/mL ± 225 ng/mL (median 300 ng/mL, range 107–821 ng/mL), while serum samples from healthy donors averaged at 50 ng/mL ± 49 ng/mL (median 35 ng/mL, range 9–199 ng/mL).
The authors concluded that the magnetic bead fluorescence immunoassay is a proof of concept that can accurately and rapidly receive protein biomarker data using antibodies bound to magnetic beads in a POC-ready device, providing a simple alternative immunoassay that could help optimize pneumonia diagnosis in low resource settings. The key features of the presented assay are a rapid fluorescence measurement below 20 minutes, a detection limit that corresponds well to the lower reference range of this inflammation serum marker, and usage of an inexpensive and robust device. The study was published in the December 2015 issue of the Journal of Immunological Methods.
Related Links:
Technische Universität München
QIAGEN Lake Constance GmbH
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Immunology News
- AI Predicts Tumor-Killing Cells with High Accuracy
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form